Is it time for a kumbaya moment on the CREATES Act? I’m not convinced
The generic and brand industry have been at war over the CREATES Act for years now.
But when the bill is taken up by the Energy & Commerce Committee Wednesday, the two sides say they won’t be throwing jabs. Despite their long-standing opposition to the bill, the branded drug industry insists they’re willing to work to get the bill passed. The generics lobby, too, says it’s ready to work with its brand counterparts.
"Our position has been very clear: we are willing to work with anyone who wants to solve this problem," Chip Davis, the Association for Accessible Medicines president and CEO, told reporters on Monday, referring to tactics some brand-name manufacturers have used to prevent generic drug makers from getting access to brand drug samples, which the CREATES Act is meant to address. "Only of late has that appeared to be the branded industry, which has been the impediment to this thing."
How likely, truly, are the two sides to work together? That’s still up for debate. PhRMA’s president and CEO Steve Ubl has said the group has worked to “develop a modified version” of the bill alongside AAM. Whether the two sides can actually get together on what those modifications are, however, remains to be seen.
But when the bill is taken up by the Energy & Commerce Committee Wednesday, the two sides say they won’t be throwing jabs. Despite their long-standing opposition to the bill, the branded drug industry insists they’re willing to work to get the bill passed. The generics lobby, too, says it’s ready to work with its brand counterparts.
"Our position has been very clear: we are willing to work with anyone who wants to solve this problem," Chip Davis, the Association for Accessible Medicines president and CEO, told reporters on Monday, referring to tactics some brand-name manufacturers have used to prevent generic drug makers from getting access to brand drug samples, which the CREATES Act is meant to address. "Only of late has that appeared to be the branded industry, which has been the impediment to this thing."
How likely, truly, are the two sides to work together? That’s still up for debate. PhRMA’s president and CEO Steve Ubl has said the group has worked to “develop a modified version” of the bill alongside AAM. Whether the two sides can actually get together on what those modifications are, however, remains to be seen.
No hay comentarios:
Publicar un comentario